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Patients with similar tumor types can have markedly dif-
ferent responses to the same therapy. The development
of new treatments would benefit significantly, therefore,
from the introduction of imaging methods that allow an
early assessment of treatment response in individual
patients, allowing rapid selection of the most effective
treatment [1]. We have been developing methods for
detecting the early responses of tumors to therapy. This
has included a targeted MRI contrast agent for detecting
tumour cell death [2] and MR imaging of tumor cell
metabolism using hyperpolarized
13C-labelled cellular
metabolites. Nuclear spin hyperpolarization techniques
can increase sensitivity in the MR experiment by
>10,000x. This has allowed us to image the location of
labeled cell substrates and, more importantly, their
metabolic conversion into other metabolites. We
showed that exchange of hyperpolarized
13C label
between lactate and pyruvate, in the reaction catalyzed
by the enzyme lactate dehydrogenase, could be imaged
in tumors and that this flux was decreased in treated
tumors undergoing drug-induced cell death [3]. We
compared this method for detecting treatment response
with measurements of fluorodeoxyglucose uptake [4].
We have shown, more recently, that hyperpolarized
[1,4-
13C]fumarate can be used to detect tumor cell
necrosis post treatment [5]. We have also shown that
tissue pH can be imaged from the ratio of the signal
intensities of hyperpolarized H
13CO3- and
13CO2 follow-
ing intravenous injection of hyperpolarized H
13CO3-.
The technique was demonstrated with a study on a
mouse tumor model, which showed that the average
tumor pH was significantly lower than the surrounding
tissue. Since bicarbonate is already used intravenously in
humans, we propose that this technique could be used
clinically to image disease and response to treatment [6].
Published: 24 September 2010
References
1. Brindle K: New approaches for imaging tumour responses to treatment.
Nature Rev Cancer 2008, 8:1-14.
2. Krishnan AS, Neves AA, de Backer MM, Hu DE, Davletov B, Kettunen MI,
Brindle KM: Detection of cell death in tumors using MRI and a
gadolinium-based targeted contrast agent. Radiology 2008, 246:854-862.
3. Day SE, Kettunen MI, Gallagher FA, Hu DE, Lerche M, Wolber J, Golman K,
Ardenkjaer-Larsen JH, Brindle KM: Detecting tumor response to treatment
using hyperpolarized 13C magnetic resonance imaging and
spectroscopy. Nat Med 2007, 13:1382-1387.
4. Witney TH, Kettunen MI, Day SE, Hu DE, Neves AA, Gallagher FA, Fulton SM,
Brindle KM: A comparison between radiolabeled fluorodeoxyglucose
uptake and hyperpolarized C-13-labeled pyruvate utilization as methods
for detecting tumor response to treatment. Neoplasia 2009, 11:574-582.
5. Gallagher FA, Kettunen MI, Hu DE, Jensen PR, Zandt RI, Karlsson M,
Gisselsson A, Nelson SK, Witney TH, Bohndiek SE, Hansson G, Peitersen T,
Lerche MH, Brindle KM: Production of hyperpolarized [1,4-13C)]malate
from [1,4-13C)]fumarate is a marker of cell necrosis and treatment
response in tumors. Proc Natl Acad Sci U S A 2009, 106:19801-19806.
6. Gallagher FA, Kettunen MI, Day SE, Hu DE, Ardenkjær-Larsen JH, in ‘t
Zandt R, Jensen PR, Karlsson M, Golman K, Lerche MH, Brindle KM:
Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-
labeled bicarbonate. Nature 2008, 453:940-943.
doi:10.1038/nrc2289
Cite this article as: Brindle: Detecting tumor responses to treatment
using hyperpolarized 13C magnetic resonance spectroscopic imaging.
BMC Proceedings 2010 4(Suppl 2):O24.
Correspondence: kmb1001@cam.ac.uk
Department of Biochemistry, University of Cambridge and Cancer Research
UK Cambridge Research Institute, Cambridge, UK
Brindle BMC Proceedings 2010, 4(Suppl 2):O24
http://www.biomedcentral.com/1753-6561/4/S2/O24
© 2010 Brindle; licensee BioMed Central Ltd.